Just last year, congress passed the Inflation Reduction Act. The law contains several drug pricing measures hated by the pharmaceutical industry, including restrictions to price increases and Medicare negotiations. Eric Sagnowsky talked with Stacie Dusetzina, a professor at Vanderbilt University's Department of Health Policy, about what we can expect.
Also on the show, Fierce's Analee Armstrong and Gabrielle Mason reflect on the biotech industry last year and our expectation for 2023—plus, this week's headlines.
To learn more about topics in this episode:
2023 forecast: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation'
2023 forecast: Biotech plummeted from 'the highest of highs' in 2022. Will the sun shine again next year?
Fierce Biotech Fundraising Tracker: Enlaza launches with $61M; Enveda brings in $68M
Fierce Biotech Layoff Tracker: Layoffs strike 119 companies in 2022
Theranos' Elizabeth Holmes labeled a 'flight risk' as she asks to delay prison sentence during appeal
Eli Lilly shut out of Alzheimer's fast lane with FDA rejection for donanemab
Health group lambasts CBS ‘60 Minutes’ segment for overt promotion of Novo Nordisk’s obesity med Wegovy
Eli Lilly to pour $450M more into diabetes drug plant in North Carolina, add 100 jobs
Frosty funding forecast forces Finch to stop phase 3 trial, lay off 95% of staff and seek buyers for assets
The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.
See omnystudio.com/listener for privacy information.
This year kicks off the second decade of Fierce Medtech’s annual Fierce 15 report. Not surprisingly, the startups featured on this year’s list are raising the bar for medtech developers everywhere. Staff writer Andrea Park and Editor-in-Chief Ayla Ellison discuss a few of the 15 startups that...
Is it all bad news in the bear market? Not necessarily.
After a tumultuous couple of years, many biotechs are looking for signs of improvement in 2023. After all, the biotech sector felt the market pain acutely, particularly over the last 18 months: 2022 marked the longest period of net negative...